In epithelial cancers, ST6GAL1 has been shown to regulate α2,6 sialylation and impart tumor-initiating cell (TIC) phenotypes, including sustained proliferative capacity, upregulation of TIC markers (CD133, ALDH1), sphere formation capacity, resistance to cell death induced by chemotherapies, growth factor withdrawal, and inflammatory mediators (15–24). This evidence concerns the gene ST6GAL1 and neoplasm.